Eli Lilly | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 36.4B 2.35B 2025-03
Abbott USD 13.44B 435M 2025-06
ALKERMES USD 505.96M 62.23M 2025-06
Amgen USD 23.01B 91M 2025-03
AstraZeneca USD 33.54B 4.41B 2025-06
Baxter International USD 3.48B 3.03B 2025-03
Biogen USD 3.18B 2.11B 2025-06
Bristol-Myers Squibb USD 27.53B 3.46B 2025-06
Drreddys Laboratories INR 131.95B 2.65B 2024-12
Eli Lilly USD 30.07B 1.69B 2025-03
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 20.83B 866M 2025-03
Glaxosmithkline GBP 21.7B 238M 2024-12
J&J USD 56.9B 6.58B 2025-03
Medtronic USD 12.88B 1.04B 2025-04
Merck USD 25.17B 3.25B 2025-03
Neurocrine Biosciences USD 522.9M 15.2M 2025-03
Novartis USD 31.71B 95M 2025-06
Novartis USD 28.69B 560M 2024-12
Novo Nordisk 236.12B 27.76B 2025-03
Perrigo USD 1.07B 29.6M 2025-03
Pfizer USD 36.45B 6.54B 2025-03
Prestige Brands USD 106.62M 4.08M 2025-03
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 32.22B 3.06B 2025-03
Sanofi 29.16B 865M 2024-12
United Therapeutics USD 527.1M 194.4M 2025-06
Zoetis USD 3.38B 27M 2025-03


Eli Lilly Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.